Multiple sclerosis (MS) is a chronic, immune-mediated inflammatory demyelinating disease of the central nervous system (CNS). Approximately 400,000 Americans have MS, although this may be an underestimate, and the disease affects about twice as many women as men. Some patient groups, such as African Americans, experience a more rapid and severe clinical course. MS is the most common nontraumatic cause of permanent disability among young adults. The annual cost of MS in the United States is estimated to be $28 billion.
ICER’s review will incorporate treatments for two types of MS. The most common form of the disease is relapsing-remitting MS (RRMS), which affects 85% to 90% of patients with MS. RRMS is characterized by periodic relapses characterized by neurologic symptoms that diminish or resolve with treatment. The report will also review treatments for primary-progressive MS (PPMS), which affects approximately 10-15% of MS patients. PPMS is characterized by steadily worsening neurologic function without remissions or acute episodes.
Interventions of Interest:
- Daclizumab (Zinbryta®, Biogen/AbbVie)
- Glatiramer acetate (Copaxone®, Teva)
- Glatiramer acetate (Glatopa®, Sandoz (Novartis))
- Interferon beta-1a (Avonex®, Biogen)
- Interferon beta-1b (Betaseron®, Bayer)
- Interferon beta-1b (Extavia®, Novartis)
- Interferon beta-1a (Rebif®, EMD Serono)
- Peginterferon beta-1a (Plegridy®, Biogen)
- Dimethyl fumarate (Tecfidera®, Biogen)
- Fingolimod (Gilenya®, Novartis)
- Teriflunomide (Aubagio®, Sanofi-Genzyme)
- Alemtuzumab (Lemtrada®, Sanofi-Genzyme)
- Natalizumab (Tysabri®, Biogen)
- Ocrelizumab (Ocrevus®, Roche/Genentech)
- Rituximab (Rituxan®, Roche/Genentech)
Date of Review: February 2017
1233 Preservation Park Way
Oakland, CA 94612
The California Technology Assessment Forum convened to discuss ICER's report on treatments for Multiple Sclerosis.
Public comments on the Draft Evidence Report.